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Introduction
The completion of the human genome project together
with the development and implementation of microarray
technologies have opened new opportunities for progress
in cancer research. For instance, an increasing number of
molecular markers with prognostic and diagnostic poten-
tial have been identified in a broad range of human can-
cers by cDNA microarray analysis [1]. Thus, there are great
expectations from the use of this technology in clinical
oncology and on their potential impact in improving the
management of cancer patients. However, routine appli-
cation of microarrays in clinical practice still requires sig-
nificant efforts to standardize the array manufacturing
techniques, assay protocols and analytical methods used
to interpret the data. Moreover, progress in the effective-
ness of microarray technology in generating relevant
information in this field has simultaneously highlighted
the major challenge of integrating experimental data with
clinical and epidemiological parameters. Thus, with the
intent of focusing on the achievements of this fast-moving
strategy in addressing the pressing needs of oncological
practice and the aim of discussing its limitations and pros-
pects, the authors of this report organized a Workshop on
"Microarray Technologies in Clinical Oncology: Potential and
Perspectives" held in Rome, Italy, in late June 2005. Inves-
tigators with complementary expertise on the application
of microarray technology in clinical oncology presented
their recent findings and debated critical aspects regarding
diagnostic and prognostic applications and current trends
in the use of this technology for monitoring and predict-
ing clinical response to treatment of cancer patients. This
meeting report summarizes the main contributions and
underlines some critical issues, which need to be
addressed to enhance the effectiveness of this potential
powerful new technology in clinical oncology.
Microarray technology as a diagnostic and 
prognostic tool
Microarray technologies have been extensively used to
evaluate genetic markers and changes in gene expression
associated with cancer onset and progression for certain
types of solid tumors [2]. Ulrich Hengge (Duesseldorf,
Germany) discussed his findings on human melanoma: a
cancer whose progression from benign to various levels of
malignant behavior has been extensively characterized at
the histopathological level. Microarray technology identi-
fied two potential independent predictors of malignant
behavior; activator of S phase kinase (ASK/HuDbf4) and
tumor potentiation region (Tpr). Both were significantly
over expressed in primary melanomas, subcutaneous
melanoma metastases, and metastatic melanoma cell
lines (BML, MV3, M13) as opposed to congenital nevi.
Moreover, it was found that approximately 86% of the
melanoma metastases over expressed ASK/HuDbf4 and
Tpr as compared to other markers commonly used for
detection of melanoma progression/metastasis such as
CD146/MUC18 (13%) and c-Met (53%) [3]. In an
attempt to identify genes relevant for human melanoma
progression, Marco Paggi (Rome, Italy) provided cDNA
array-based evidence of clear-cut RNA over expression of
Published: 07 February 2006
Journal of Translational Medicine2006, 4:8 doi:10.1186/1479-5876-4-8
Received: 13 December 2005
Accepted: 07 February 2006
This article is available from: http://www.translational-medicine.com/content/4/1/8
© 2006Gabriele et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2006, 4:8 http://www.translational-medicine.com/content/4/1/8
Page 2 of 5
(page number not for citation purposes)
the ferritin light chain (FTL) in the LM metastatic cell line,
derived from a supra-clavicular lymph node metastasis.
Immunohistochemical analysis validated this finding
demonstrating that ferritin is consistently over expressed
in paired samples in which autologous lymph node
melanoma metastases were compared to primary tumors.
Similarly, Bertrand Rihn (Nancy, France) described array-
based portraits of normal and cancerous pleura relevant
to the understanding of asbestos-mediated carcinogene-
sis. In three independent studies, overexpression of both
FLT and TXN (thioredoxin) was consistently associated
with the acquisition of a malignant phenotype.
Microarray technology has provided the opportunity to
begin a comprehensive molecular and genetic profiling of
human breast cancer [4]. Although the estrogen receptor
(ER) has played a major role in defining the molecular
composition of breast cancer, array-based studies revealed
that this disease is considerably more heterogeneous than
predicted by traditional histopathological methods.
Marco Pierotti (Milan, Italy) reviewed his experience with
microarray studies aimed at the molecular classification of
BRCAX, familial breast cancers that do not involve the
BRCA1 and BRCA2 genes. Pierotti's group proposed that
these BRCA1/2-independent tumors may carry mutations
influencing susceptibility through gene-gene or gene-
environment interactions though a low penetrance proc-
ess. Gene expression profiling, adjusted for ER status
through the application of a multivariate linear model,
could clearly distinguish BRCA1/2 from BRCAX cases sug-
gesting the involvement in BRCAX cases of familial genes
acting in breast cancer-specific pathways different from
those involving BRCA1 and BRCA2. Cristous Sotiriou
(Bruxelles, Belgium) reported on an attempt to link a
computational "genomic signature" grade (GG) to the
conventional histological grading (HG) of breast cancer.
The rationale for this study stemmed from the considera-
tion that, although HG is recognized to provide reliable
prognostic information when applied to grade 1 (low
risk) and 3 (high risk) tumors which are clearly associated
with different prognoses, it is not as accurate for grade 2
tumors that pose the greatest difficulties in treatment deci-
sion making. HG2 tumors present survival profiles similar
to the total (non-graded) population. In addition, HG2
tumors represent a substantial proportion (40–50%) of
cases [5]. Sotiriou's group observed that the prognostic
value of GG was greater than HG in defining grade 1 and
3 tumors since the GGI score (gene-expression grade
index) was consistent across four validation data sets
including over 500 patients. Moreover, GG allowed split-
ting HG2 into two groups: HG2/GG1 and HG2/GG3,
with prognoses that were similar toHG1 and HG3 tumors,
respectively. Thus, when compared to the HG classifica-
tion, the GG approach represents a highly versatile and
more powerful tool for the objective assessment of inter-
mediate grade breast cancer, which could lead to an easier
decision-making process for breast cancer management.
In the hematological field, cDNA microarrays have con-
tributed to an increasingly well-defined molecular taxon-
omy of leukemias and lymphomas. This has led to the
segregation of morphologically identical tumors accord-
ing to molecular patterns predictive of distinct clinical
outcomes [6-8]. Moreover, gene expression studies led to
the discovery of new hematological disease subclasses
characterized by unique molecular profiles suggesting the
development of diagnostic strategies based solely on gene
expression profiling. During the workshop, it was
reported that oligonucleotide microarrays (Affymetrix)
were successfully utilized within a routine diagnostic
workflow to distinguish 13 clinically relevant distinct sub-
types of adult leukemias including acute myeloid leuke-
mia (AML), acute lymphoid leukemia (ALL), chronic
lymphocytic leukemia (CLL) and chronic myeloid leuke-
mia (CML). A re-sampling approach confirmed the high
predictive accuracy (95.1%) and specificity (median,
93.8%) of the microarray method (Torsten Haferlach,
Munich, Germany). Robin Foà (Rome, Italy) observed
that great research efforts are currently focused on the
identification of gene patterns capable of distinguishing
patients with different outcomes, with the ultimate goal of
providing novel and reliable prognostic tools. In patients
with adult ALL, DNA microarray experiments allowed the
identification of patterns specific for well characterized
molecular abnormalities such as ALL1/AF4, E2A/PBX1,
TEL/AML1 and, to a lesser extent, BCR/ABL, or associated
with immunophenotypic characteristics such as the cellu-
lar origin of a leukemia and the degree of leukemic cell
differentiation [9,10]. In both T- and B-lineage ALL,
response to treatment and overall response appeared to be
associated with specific gene expression profiles. In CLL,
the prognostic role of Zap-70 has emerged from a gene
profile study [11]. Of note, gene expression profiling pro-
vided insights into the pathogenesis of multiple myeloma
(MM), stratifying patients according to its degree of
aggressiveness [8]. In addition, and probably more rele-
vantly, gene profile analysis has identified new prognostic
markers in adult ALL, as well as potential new targets for
innovative therapeutic strategies [12,13]. Recently, the
accumulation of data from microarray studies has allowed
the development of prediction models, which may com-
plement standard predictive systems currently applied in
the clinics [14]. These prediction models are based on
ranking the specific weight of each potential marker and
the inclusion of the most relevant into a unified algorithm
to build clinically relevant categories to which individual
patients are assigned. Miguel Piris (Madrid, Spain)
reported that predictive systems are under development
for Hodgkin's lymphoma, CLL, cutaneous T-cell lympho-
mas (CTCL), mantle cell lymphoma (MCL) and diffuseJournal of Translational Medicine 2006, 4:8 http://www.translational-medicine.com/content/4/1/8
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large B-cell lymphoma (DLBCL). He reported that an out-
come prediction model for DLBCL incorporating gene sig-
nature-based information and the International
Prognostic Index (IPI) had a slightly higher predictive
capacity than models based purely on expression analysis
and that this corresponded to a better discrimination of
patients with different outcome. In summary, the predic-
tive accuracy of these models should be tested in prospec-
tive studies with the aims of assessing risk specific for each
case and suggesting optimal treatment selection for indi-
vidual patients.
Monitoring and predicting responses in clinical 
trials by means of microarrays
The increasing use of microarray technology for character-
izing the transcriptional profile of tumors opened the
opportunity to develop potent tools for prediction of
response to treatment and for the identification of novel
therapeutic targets. The genome-wide perspective offered
by microarrays has allowed the focus of drug develop-
ment to shift towards targeted therapeutics acting on spe-
cific molecular targets. For instance, it has been reported
that growth factor signals are mutated in a number of can-
cers including colorectal cancer [15]. Advances in micro-
array technology have opened the possibility of focusing
current research efforts on the development of novel
agents capable of targeting key proteins such as phos-
phatidylinositol-3-kinase (PI3K) and chaperone HSP90,
acting in growth factor signaling pathways. Paul Clarke
(Surrey, UK) highlighted how DNA microarray technol-
ogy holds great potential for elucidating gene expression
patterns underling the complex cellular effects and mech-
anisms of action of targeted cancer therapeutics, thus
enhancing the opportunities for discovery and develop-
ment of several types of anticancer agents.
Although there is circumstantial evidence that the activa-
tion of the anti-tumor immune response may be critical in
affecting the natural or treatment-induced history of can-
cer, the complex interactions underling this phenomenon
remains largely unknown [16]. For instance, it is still
unclear whether factors related to the genetic background
of patients are predominant or whether distinct character-
istics of individual tumors may facilitate or inhibit
immune responses during therapy. The advancement of
microarray technology exerted a significant impact on the
understanding of crucial factors affecting response to ther-
apy [17]. Francesco M. Marincola (Bethesda, MD, USA)
pointed out that current technologies allow genome wide
analyses of tumor/host interactions at the tumor site that
can be evaluated in the context of the genetic background
of individual patients. For instance, microarray analysis
applied to serial sampling of tumor lesions may allow the
identification of biomarkers predictive of immune
responsiveness to a given treatment. In addition, serial
sampling of the same lesions using fine needle aspirates
before and during treatment may provide information
about the mechanisms of action of the treatment and its
biological effects. Marincola also described a study aimed
at characterizing the mechanisms by which systemic
administration of high-dose interleukin-2 (IL-2) was
effective for the treatment of metastatic melanoma. Micro-
array analysis profiled early transcriptional changes in cir-
culating mononuclear cells and in the microenvironment
of melanoma metastases. Interestingly, it was established
that although this cytokine has minimal effects on migra-
tion, activation and proliferation of T cells at the tumor
site, it induces a massive production of innate immune
effector molecules such as chemoattractants and cytotoxic
mediators, likely released by monocytes and NK cells.
Moreover, a substantial activation of genes involved in
inflammation was reported in the peripheral blood of the
same patients [18]. In another study, Eleonora Aricò
(Rome, Italy) described how DNA microarrays were used
for the profiling gene expression induced in peripheral
blood mononuclear cells by IFN-α administered to stage
IV melanoma patients in combination with epitope-spe-
cific immunization. Aricò showed that IFN-α induced a
well-defined "IFN signature", which included not only the
typical IFN-induced genes, but also several genes typically
involved in the immune response. Of note, a defined set
of the genes up-regulated in PBMC of the IFN-treated
melanoma patients was consistently similar to the genes
whose expression was up-regulated in dendritic cells gen-
erated after a 3-day in vitro exposure to GM-CSF and IFN-
α as compared to cells treated with GM-CSF alone. This
study could also provide insights into the mechanisms
contributing to the in vivo anti-tumor activity of IFN-α
through the enhancement of monocyte and dendritic cell
functions [19,20]. The extraordinary potential of microar-
ray technology in the field of clinical oncology was further
discussed by Monica C. Panelli (Bethesda, MD, USA).
They used multiplexed protein array platforms to charac-
terize the cytokine outburst that follows systemic IL-2
administration to patients with renal cell cancer undergo-
ing high dose IL-2 therapy and correlated the findings
with results obtained by transcriptional profiling. Several
soluble factors were released in the serum of IL-2-treated
patients that can induce powerful systemic and vascular
inflammatory immune and non-immune reactions. These
results underline how DNA and protein microarrays rep-
resent powerful tools providing distinct and yet comple-
mentary information essential for understanding complex
phenomena such as the systemic response to cytokine
immunotherapy.
The influence of the genetic background of patients on
treatment outcome was discussed by Marincola
(Bethesda, MD, USA) and Panelli (Bethesda, MD, USA).
Short oligonucleotide (18 to 22 oligonucleotide) microar-Journal of Translational Medicine 2006, 4:8 http://www.translational-medicine.com/content/4/1/8
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rays represent a powerful tool for genome-wide screening
of genetic variations such as single nucleotide polymor-
phisms (SNPs), which can be used to identify genetic dif-
ferences potentially responsible for divergent responses to
therapy [21]. They both described the development of an
oligo-based microarray platform for the evaluation of
SNPs in cytokines, cytokine-receptors and other immune
modulators known to play crucial roles in the regulation
of immune functions and hence potentially responsible
for the modulation of the complex interactions occurring
at the tumor/host interface [22]. As an example, Marin-
cola described the analysis of two prototype populations
to identify genetically determined markers of functional
relevance. He described differences between Chinese and
Caucasian subjects in the response of peripheral mononu-
clear cells to IL-2 that could be identified by transcrip-
tional profiling. These functional differences could be
linked to distinct genetic patterns in genes associated with
the IL-2 pathway. Distinct SNPs were identified in these
populations that could be responsible for the observed
functional differences. These studies suggest that the com-
bination of high-throughput genomic and transcriptional
analyses could link genotypic to phenotypic characteris-
tics and may represent a powerful strategy for assessing
inter-patient variability, opening a new perspective for
better patient selection and tailoring of therapy strategies.
Impact of DNA microarrays on clinical research: 
technical issues and prospects of 
implementation
The workshop concluded with a roundtable discussion of
critical issues associated with the introduction of microar-
ray technology to the practice of clinical oncology. There
was general agreement that a series of scientific, ethical
and legal concerns must be resolved before these genomic
tools can become part of the armamentarium of clinical
practitioners [23]. The foremost concern centers on the
validity and accuracy of data generated using different
microarray platforms. This problem was exemplified by
reports describing considerable variability in results
obtained with the use of different platforms to analyze
similar experiments carried out in the same or different
laboratories. For example, Marco Pierotti (Milan, Italy)
presented microarray data from a study on a leukemic
model represented by U937-PML/RAR, U937-AML1/
ETO-HA and U937-PLZF/RAR cell clones. He observed
that cDNA (Amersham-Mol. Dyn.) and Affymetrix plat-
forms generated comparable results in controlled experi-
ments where differential expression was strong; however,
results were complementary in complex biological sys-
tems with weak differential expression. In this regard, it
was emphasized by Lucia Gabriele (Rome, Italy) that the
correct use of controls, together with an experimental
design carefully tailored to the phenomenon under study
may reduce many of these inconsistencies. Considerable
attention was paid to the need for standardization of pro-
cedures for the collection of biological samples to be used
for microarray analyses. Monica Panelli (NIH, Bethesda,
USA) stressed that correct handling procedures are critical
to the generation of reproducible and meaningful data. At
present, there are still concerns about the ability of micro-
array analyses to identify biologically important phenom-
ena when used as a single tool. Marco Petilli (Milan Italy)
stated that it was generally agreed that results obtained
from microarrays should be validated using independent
methods such as quantitative real-time PCR or analyses of
the protein encoded by the gene of interest. It was con-
cluded that major concerns related to the quality of bio-
logical samples could be resolved by the adoption of
carefully standardized procedures for tumor sampling,
identification, and storage. This would result in the crea-
tion of high quality tissue banks linked to searchable data-
bases containing the clinical and biological characteristics
of the samples.
The use of microarrays in clinical oncology raises another
critical issue: the management of the tremendous volume
of data generated in the context of different types of anal-
yses. It was highlighted that this could be turned into an
advantage since it may be that complex relationships in
gene expression patterns can be resolved only when very
large data sets are available for analyses. However, in
order to achieve this goal, more efficient data manage-
ment systems are required. For instance, James F. Reid
(Milan, Italy) pointed out that in building predictive
models from gene expression profiling experiments, it is
also important to report proper estimates of classification
accuracies and validate promising classifiers on independ-
ent data to further evaluate their clinical utility [24]. More-
over, what still remains difficult is to link array results to
factual or bibliographical data and retrieve information
that is highly structured and often rare. In this regard, Ber-
nard Rihn (Nancy, France) presented a new tool, Docu-
mentation and Information Library (DILIB) that makes it
possible to link hundreds of differentially expressed genes
through their Single Identifier or GenBank accession
number to hundreds of Medline records. DLIB can auto-
matically retrieve, analyze and compare thousands of
non-trivial descriptors related to gene clusters [25]. Cer-
tainly, future implementations in this field will allow the
establishment of better links between gene expression pat-
terns and diagnosis, treatment outcome and other clinical
parameters. This, in turn, may lead to the more accurate
definition of diseases, prospective risk assessment, precise
staging and prediction of response to treatment.
Conclusion
The expectations for what might be gained from high
throughput microarray technology in clinical oncology
are high as its utilization in clinical practice could mark-Publish with BioMed Central    and   every 
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edly improve our current strategies for the diagnosis of
cancer and prediction of the clinical outcome. This in turn
may lead to the identification of treatments optimized
according to the genetic background of individual
patients and the biological characteristics of their tumors.
However, many concerns about microarray-based experi-
mentation need to be resolved regarding sample handling
and data interpretation in order to fulfill these expecta-
tions. This can only be achieved by establishing a close
cooperation between experts in microarray technologies,
"trialists" and clinicians. A strategic international cooper-
ation involving public and private institutions is also
needed in order to exploit the potentialities of these new,
continuously changing, microarray technologies in clini-
cal oncology. Indeed, the true potential of this powerful
tool will be fully exploited only when networks of excel-
lence capable of correctly performing large validation
studies and of directing data into new translational stud-
ies are established. In addition, the routine application of
microarray technologies in clinical oncology would raise
some relevant legal, ethical, social and regulatory issues,
which have been poorly addressed so far. Therefore,
efforts should be undertaken to achieve maximal techni-
cal consistency and standardization and to define specific
and comprehensive regulatory frameworks for addressing
the many unresolved issues. The authors hope that that
the Workshop "Microarray Technologies in Clinical Oncol-
ogy: Potential and Perspectives" will have contributed to a
better understanding of the "state of the art" of this prom-
ising field of cancer research. In addition, we have hope-
fully provided a clearer definition of some critical issues
that need to be addressed in order to translate the great
expectations of the scientific community into realities for
the better management of cancer patients.
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